More Vaccinations, Experimental Drugs as Potential Ebola Contacts Rise

The World Health Organization predicts the number of cases in Democratic Republic of Congo will rise up to 300 by July.

Sukanya Charuchandra
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ISTOCK, DK_PHOTOSThe ongoing Ebola outbreak in Democratic Republic of Congo has claimed 25 lives as of yesterday (May 29), reports Reuters, taking the total number of cases in the country to 54. This is DRC’s ninth tussle with the hemorrhagic fever since its first appearance in 1976.

The World Health Organization (WHO) is administering ring vaccinations to people who have had suspected contact, either directly or indirectly, with an Ebola patient. This means immunizing and monitoring all the individuals who have had potential contacts with patients, 906 people so far. Of those, more than 360 contacts vaccinated before Monday, reports The New York Times. The operation began in Mbandaka, a city of more than 1 million residents, last week. The rural town of Bikoro is the second site for vaccinations, which began this Monday (May 28).

A number of experimental drugs, including antibodies and antiviral options, are also available, according to Nature. WHO is awaiting the approval of DRC’s Ministry of Health to deploy them and begin trials, reports CNN.

A 2014-2016 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Sukanya Charuchandra

    Sukanya Charuchandra

    Originally from Mumbai, Sukanya Charuchandra is a freelance science writer based out of wherever her travels take her. She holds master’s degrees in Science Journalism and Biotechnology. You can read her work at sukanyacharuchandra.com.

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours